The research project, AID-ICU trial
– the aim of the trial is to determine whether treatment of delirium with haloperiodol has a beneficial effect in critically ill patients with delirium. Critically ill patients admitted to the intensive care unit, are at high risk of developing delirum.
Delirium is the clinical representation of a dysfunctional brain caused by e.g. critical illness. The trial compares haloperiodol with placebo (saline)to assess whether treatment with haloperiodol has a beneficial effect in patients admitted to the intensive care unit.
Find more detailed information for participants here (click here).
The trial was initiated in June 2018 and is expected to be completed June 2020. The final results of the trial are expected to be finished in the autumn 2020. There is a 1-year follow-up of all trial participants. You will be either interviewed by phone asking about your quality of life or you will have a home visit with a interview about your quality of life and cognitive function. The results of the 1-year follow-up are expected completed in the summer 2021.